treprostinil sodium - Profile

What are the generic drug sources for treprostinil sodium and what is the scope of patent protection?

Treprostinil sodium is the generic ingredient in one branded drug marketed by Liquidia Tech and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Treprostinil sodium has twelve patent family members in six countries.

Summary for treprostinil sodium

International Patents:	12
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for treprostinil sodium

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for treprostinil sodium

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for treprostinil sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes			Y
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes			Y
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes			Y
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes

International Patents for treprostinil sodium

Country	Patent Number	Title	Estimated Expiration
Japan	2019519489	肺高血圧症を治療するための乾燥粉末トレプロスチニル
European Patent Office	3452170	POUDRE SÈCHE DE TRÉPROSTINIL POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION)
Australia	2017261317	Dry powder treprostinil for the treatment of pulmonary hypertension
European Patent Office	3452170	POUDRE SÈCHE DE TRÉPROSTINIL POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION)
Israel	319790	טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי (Dry powder treprostinil for the treatment of pulmonary hypertension)
Israel	262720	טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי (Dry powder treprostinil for the treatment of pulmonary hypertension)
Israel	262720	טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי (Dry powder treprostinil for the treatment of pulmonary hypertension)

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for Treprostinil Sodium

Last updated: February 3, 2026

---

Executive Summary

Treprostinil sodium, marketed primarily under the brand Remodulin, is a prostacyclin analogue indicated for pulmonary arterial hypertension (PAH). The drug has gained prominence due to its unique pharmacological profile and strong positioning within the PAH treatment landscape. This report evaluates key market drivers, competitive landscape, regulatory environment, and financial forecasts to inform investment decisions.

---

Overview of Treprostinil Sodium

Parameter	Details
Generic Name	Treprostinil sodium
Brand Name	Remodulin (AbbVie), others
Indication	Pulmonary arterial hypertension (WHO Group 1)
Mechanism of Action	Prostacyclin analogue, vasodilation, antiproliferative effects
Formulation	Continuous IV and subcutaneous infusion, inhalation, and oral formulations (approved in some markets)

Market Landscape & Dynamics

Market Size and Growth

Year	Global PAH Market (USD billion)	Treprostinil Market Share	Compound Annual Growth Rate (CAGR) (2023–2028)	Key Drivers
2023	2.0	~15% (primarily via Remodulin)	9%	Rising PAH prevalence, newer formulations, residual unmet needs

Sources project the global PAH market to reach USD 2.8 billion by 2028, driven by increased diagnosis, advanced therapeutics, and expanded indications.

Market Drivers

• Increasing Prevalence of PAH: Estimated at 15–50 cases per million, with notable underdiagnosis.
• Therapeutic Advances: Development of inhaled and oral formulations enhances patient compliance.
• Pipeline and Innovation: Emerging alternatives and combination therapies influence market share.

Competitive Landscape

Drug	Mechanism	Formulation	Market Share (2023)	Key Competitors
Remodulin	Prostacyclin analogue	IV, subQ	~70%	Iloprost, Epoprostenol, Bosentan, Riociguat
Bosentan	Endothelin receptor antagonist	Oral	~15%	Ambrisentan
Riociguat	Soluble guanylate cyclase stimulator	Oral	~10%	Sildenafil
Others	Various	Inhalation, combination	~5%	Aspirin, Macitentan

Despite competing therapies, treprostinil's versatility in formulation sustains its market position.

---

Regulatory Environment

• FDA (USA): Treprostinil (Remodulin) approved since 2002 for PAH. Device approvals expand to inhalation (Tyvaso, marketed by United Therapeutics).
• EMA (Europe): Approval similar for PAH treatment; some formulations face market restrictions.
• Emerging Markets: Regulatory pathways are developing; approval status varies significantly.

Financial Trajectory of Treprostinil Sodium

Revenue Forecasts (2023–2028)

Year	Estimated Revenue (USD million)	Assumptions	Growth Factors
2023	295	Market penetration stable; price adjustments	Established brand, limited generic competition
2024	320	Slight market expansion	Increased adoption in emerging markets
2025	355	New formulation introductions	Clinical evidence enhances prescriber confidence
2026	395	Expansion into oral formulations	Growing patient population
2027	440	Market penetration increases	Competitive pressures evaluated
2028	490	Broad adoption, potential biosimilar entry	Pipeline maturation

Note: These projections assume moderate market growth, no major patent expirations, and successful regulatory approvals for additional formulations.

Profitability and Cost Factors

Parameter	Details
Pricing Strategy	Premium pricing justified by clinical benefits
Manufacturing Cost	Estimated at 10–15% of gross revenue (variable)
Margins	Expected gross margin of 60–70%

---

Investment Risks and Considerations

Risk Factor	Impact	Mitigation Strategies
Patent Expirations	Loss of exclusivity from 2030	Invest in pipeline; develop new formulations
Competition	Market share erosion	Differentiate via delivery methods; clinical data
Regulatory Delays	Market access hurdles	Engage early with agencies; robust clinical data
Pricing Pressures	Revenue compression	Value-based pricing; geographic diversification

---

Comparison with Similar Therapeutics

Parameter	Treprostinil (Remodulin)	Epoprostenol	Iloprost	Oral Prostacyclin Agonists
Approval Year	2002	1995	2004	2019 (some markets)
Formulations	Continuous IV, subQ, inhalation	IV	Inhalation	Oral, inhalation, injectable
Market Share (2023)	~70%	~15%	~5%	Growing but nascent
Pricing (USD/month)	$15,000–$20,000	$12,000–$16,000	$10,000–$14,000	$8,000–$12,000

---

Key Investment Considerations

• Market Stability: Treprostinil's established position offers resilience; however, markets face pricing pressure.
• Pipeline Development: Success in inhalation and oral formulations can extend lifecycle and boost revenues.
• Regulatory Trends: Favorable policies and expanded indications enhance growth prospects.
• Competitive Threats: Biosimilars and generics threaten patent-protected revenues post-2030.

---

FAQs:

Q1: What is the primary driver of treprostinil sodium’s market growth?
Answer: Increasing prevalence and diagnosis of PAH, combined with expanding formulations that improve patient adherence and quality of life.

Q2: How does treprostinil sodium compare to alternative PAH therapies regarding market share?
Answer: It holds approximately 70% of the market share within prostacyclin-based therapies, supported by its versatility in delivery methods.

Q3: When are patent expirations expected, and how could they affect revenues?
Answer: Patent protections extend into the early 2030s, after which biosimilars may enter, potentially reducing pricing power and revenues.

Q4: What are current regulatory challenges for treprostinil formulations?
Answer: Regulatory bodies scrutinize safety data for new formulations, especially inhaled and oral versions, which may face delays or restrictions.

Q5: What are potential growth opportunities for investors?
Answer: Development and commercialization of inhaled and oral formulations, expansion into emerging markets, and pipeline innovations targeting PAH.

---

Key Takeaways

• Market Position: Treprostinil sodium remains a cornerstone in PAH management, with stable revenues driven by its formulation versatility.
• Growth Drivers: Rising PAH prevalence, extended indication approvals, and new formulations are vital for sustained growth.
• Risks: Patent expirations, competitive biosimilars, regulatory hurdles, and pricing pressures pose challenges.
• Investment Outlook: Long-term prospects depend on successful pipeline expansion, regulatory navigation, and strategic pricing.

---

References

[1] MarketResearch.com, "Global Pulmonary Arterial Hypertension Market," 2023.
[2] U.S. FDA, Remodulin (treprostinil) prescribing information, 2022.
[3] EvaluatePharma, "Pharmaceutical Market Intelligence," 2023.
[4] United Therapeutics Corporation, Annual Report, 2022.
[5] European Medicines Agency, "PAH Treatment Approvals," 2023.

Note: Data and projections are hypothetical and based on current market trends and estimations for strategic purposes.